The Traditional Uses, Phytochemistry, Pharmacokinetics, Pharmacology, Toxicity, and Applications of *Corydalis saxicola* Bunting: A Review

Yanru Guo¹²†, Linjun Zhao³†, Botao Chang¹²†, Jia Yu¹, Jiangping Bao¹, Qi Yao⁴* and Jun Luo¹*²

¹Department of Pharmacy, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China, ²College of Graduate, Guizhou University of Traditional Chinese Medicine, Guiyang, China, ³Xintian Community Health Service Center of Guiyang, Guiyang, China, ⁴Department of Anesthesiology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China

**Background:** *Corydalis saxicola* Bunting (CSB) is a perennial herb belonging to genus *Corydalis* (Papaveraceae), called “Yan-huang-lian” in the Chinese folk. Traditionally, it is used to treat acute conjunctivitis, corneal pannus, acute abdominal pain, hemorrhoidal bleeding, haematochezia, swelling, hepatitis, cirrhosis and liver cancer based on traditional Chinese medicine (TCM) concepts.

**Purpose:** This review aims to summarize and analyze the pharmacokinetics, pharmacological and toxicological properties of CSB and its extracts; to highlight the relevance of modern pharmacology to traditional pharmacology; also to assess its therapeutic potential.

**Methods:** CSB related literatures were searched and screened from databases including PubMed, Web of Science and CNKI. The selected literatures provided reliable source identification evidences.

**Results:** In traditional medicine concepts, CSB has the effects of clearing away heat and detoxification, eliminating dampness, relieving pain, and stopping bleeding. Its modern pharmacology includes hepatoprotective, anticancer, anti-inflammatory, analgesic, antibacterial, anti-oxidative effects. Further, some pharmacological effects support its traditional uses. The CSB total alkaloids (CSBTA) are the main constituents isolated from this plant, and they exert the major of the pharmacological effects. Toxicological studies have shown that the toxicity of CSBTA is mild and reversible in rodents and beagle dogs.

**Conclusion:** Although the present study summarizes the botany, phytochemistry, pharmacokinetics, pharmacology, toxicity, and applications of this plant, it is still necessary to systemically evaluate the chemistry, safety and parameters related to drug metabolism of the extracts or compounds from this plant before or in clinical trials in the future. Meanwhile, cancers and inflammatory-related diseases may be new research directions of this ethnomedicine.

**Keywords:** *Corydalis saxicola* bunting, phytochemistry, pharmacokinetics, pharmacology, toxicity, traditional uses
INTRODUCTION

*Corydalis saxicola* Bunting (CSB) is a light green and soft perennial herb of *Corydalis* (family Papaveraceae). It grows in rock cliffs or alpine caves, and is mainly distributed in the south of China, including Guizhou, Guangxi, Yunnan and Sichuan provinces (Li et al., 2018a). Traditionally, the whole plant of CSB, Yan-huang-lian is used to cure diseases in the Chinese folk. It was firstly documented to have properties of clearing away heat and detoxication, removing dampness, relieving pain and hemostasis in a book named Guizhou Herbal Medicine. Nowadays, pharmacological studies have provided evidence that this ethnomedicine can treat liver diseases and also show that it also has important pharmacological activities such as anticancer, anti-inflammation (Liang et al., 2016; Xie et al., 2021). Meanwhile, CSBTA are the main active constituents to exert the pharmacological effects described as before.

Although this plant has been widely used, it has not been included in Chinese Pharmacopoeia until now. In addition, a systematic quality standard is still absent. Furthermore, the chemical, pharmacokinetic, pharmacological, toxicological studies on this plant need enhancement. Thus, CSB related chemical, pharmacokinetic, pharmacological, toxicological systematic quality standard is still absent. Furthermore, the included in Chinese Pharmacopoeia until now. In addition, a systematic quality standard is still absent. Additionally, the harvested plants are distributed in China, mostly in the southwest region (Li et al., 2018a). CSB grows in rock cliffs or alpine caves at a proper temperature of 0–30°C. Due to the harsh growth environment, wild CSB resources are insufficient. Several studies have given recommendations for the cultivation of this plant. However, in a recent study, wild and cultivated CSBs varied in composition (Xie et al., 2021).

This plant is 15–40 cm tall with well-developed taproots; stems are 1–3 cm; whole plant is glabrous and soft; they are tufted; petioles are long; leaves blade are triangular-ovate, pinnately compound, and deeply lobed, with pointed apex and coarse-toothed margin. Flowers are yellow, racemes, terminal or opposite leaves, 7–14 cm long. Floral bracts are elliptic-lanceolate, sepals 2, petals 4, stamens 6, stigma 2-lobed. Capsules are terete, slightly curved, and had 15–22 seeds (Figure 1). Most of seeds are round, and have cup-shaped caruncle covering half of the seed.

BOTANICAL DESCRIPTION

There are about 400 species of genus *Corydalis* (Papaveraceae) worldwide, mainly distributed in the northern temperate zone. Over 50% of the *Corydalis* are distributed in China, mostly in the

![Figure 1](https://example.com/figure1.png) Plant morphology of CSB (photographed and provided by Jun Luo).

PHYTOCHEMISTRY

Alkaloids were the main chemical constituents isolated from CSB. Among the 57 reported constituents, alkaloids accounted for 49 (1–49). The remaining eight were steroidal compounds (50–57) (Tang et al., 2018). The alkaloids constituents included 13 berberines (1–13), 14 protoberberines (14–27), six benzophenanthridines (28–33), two protopines (34–35), two benzyltetrahydroisoquinolines (36–37), three aporphines (38–40), two morphinines (41–42), two simple indoles (43–44), three organic amines (45–47), one simple isoquinoline (48), and one guanidinium salt (49), among which isoquinoline alkaloids accounted for the largest proportion (Table 1).

Alkaloids are a class of nitrogen-containing basic organic compounds in nature. They possess the properties of alkali-like and cyclic structures mostly. Alkaloids show a variety of pharmacological activities, including anti-oxidative, anticancer, lipid-lowering, hypoglycemic, antibacterial, and other effects (Cicero and Ertek, 2009; Cicero and Baggioni, 2016; Kukula-Koch and Wiedelski, 2017). Its nitrogen atom and cyclic structure are responsible for the main pharmacological activities (Xu et al., 2020). As we know, isoquinoline alkaloids are one of the relatively abundant alkaloids (Singh et al., 2021). Currently, most of the alkaloids isolated from CSB are isoquinolines, among which dehydrocavidine is a characteristic and one of the most abundant constituents in this plant.

Cheng et al. evaluated the quality of extracted compounds from CSB using a HPLC-DAD method (a Gemini™ C18 column, 5 µm, 250 × 4.6 mm i.d., Phenomenex Inc., CA, USA) with a gradient solvent system (20 mM aqueous ammonium acetate–acetonitrile with a flow-rate of 1.0 mL/min) at 270 and 280 nm (Cheng et al., 2008b). The dehydrocavidine content isolated from 12 batches of CSB samples from different habitats accounted for 32.71–62.83% (8.84–19.77 mg/g) of the total alkaloids. Tang et al. established the HPLC fingerprint of CSB using the Agilent Eclipse XDB-C18 (4.6 mm × 250 mm, 5 µm) column (acetonitrile:0.1% formic acid as mobile phases, gradient elution at a flow rate of 0.5 mL/min) (Tang et al., 2019).
| No. | Name               | Parts of plant | Source        | Chemical structure | Reference       |
|-----|--------------------|----------------|---------------|--------------------|-----------------|
| 1   | dehydrocavidine    | Whole plant    | Methanol extract |                  | Li et al. (2008) |
| 2   | berberine          | Whole plant    | Ethanol extract |                  | Cheng et al. (2008a) |
| 3   | palmatine          | Roots          | Ethanol extract |                  | Wu et al. (2007) |
| 4   | dehydrocheilanthifoline | Whole plant | Ethanol extract |                  | Cheng et al. (2008a) |
| 5   | coptisine          | Roots          | Ethanol extract |                  | Wu et al. (2007) |
| 6   | jatrorrhizine      | Whole plant    | CSBTA extract  |                  | Wu et al. (2015) |
| 7   | columbamine        | Whole plant    | CSB extract    |                  | Zhou et al. (1989) |
| 8   | tetradehydroscoulerine | Whole plant | Ethanol extract |                  | Li et al. (2006) |
| 9   | dehydrodiscretamine| Whole plant    | Methanol extract |                | Cheng et al. (2008a) |
| 10  | dehydroisoapocavidine | Whole plant | Methanol extract |            | Li et al. (2008) |

(Continued on following page)
| No. | Name              | Parts of plant | Source            | Chemical structure | Reference          |
|-----|-------------------|----------------|-------------------|--------------------|--------------------|
| 11  | dehydroapocavidine | Whole plant    | Methanol extract  | ![Chemical structure](#) | Cheng et al. (2008a) |
| 12  | corysamine        | Whole plant    | CSB extract       | ![Chemical structure](#) | Zhou et al. (1989)  |
| 13  | epiberberine      | Whole plant    | Methanol extract  | ![Chemical structure](#) | Xia, (2002)         |
| 14  | cavidine          | Whole plant    | Methanol extract  | ![Chemical structure](#) | Huang et al. (2012) |
| 15  | corydaline        | Roots          | Ethanol extract   | ![Chemical structure](#) | Wu et al. (2007)    |
| 16  | stylopine         | Roots          | Ethanol extract   | ![Chemical structure](#) | Wu et al. (2007)    |
| 17  | cheilanthifoline  | Whole plant    | Ethanol extract   | ![Chemical structure](#) | Cheng et al. (2008a) |
| 18  | tetrahydrocolumbamine | Whole plant    | Ethanol extract   | ![Chemical structure](#) | Ke et al. (1982)    |
| 19  | tetrahydropalmatine | Roots          | Ethanol extract   | ![Chemical structure](#) | Wu et al. (2007)    |

(Continued on following page)
| No. | Name                        | Parts of plant | Source          | Chemical structure   | Reference          |
|-----|-----------------------------|----------------|-----------------|----------------------|--------------------|
| 20  | canadine                    | Whole plant    | Ethanol extract | ![Chemical structure](image1) | He et al. (2014)   |
| 21  | scoulerine                  | Whole plant    | Ethanol extract | ![Chemical structure](image2) | Cheng et al. (2008a) |
| 22  | β-hydroxystilopine          | Whole plant    | Ethanol extract | ![Chemical structure](image3) | Ke et al. (1982)   |
| 23  | (+)-thalictrifoline         | Whole plant    | Methanol extract| ![Chemical structure](image4) | Huang et al. (2012) |
| 24  | (−)-corynoxidine            | Whole plant    | Methanol extract| ![Chemical structure](image5) | Huang et al. (2012) |
| 25  | 4-nitroisoapocavidine       | Whole plant    | Methanol extract| ![Chemical structure](image6) | Huang et al. (2012) |
| 26  | (+)-1-nitroapocavidine      | Whole plant    | Methanol extract| ![Chemical structure](image7) | Huang et al. (2012) |
| 27  | 2,9-dihydroxy-3,11-dimethoxy-1,10-dinitrotetrahydroprotoberberine | Whole plant | Methanol extract | ![Chemical structure](image8) | Huang et al. (2012) |
| 28  | sanguinarine                | Whole plant    | Methanol extract| ![Chemical structure](image9) | Huang et al. (2012) |

(Continued on following page)
| No. | Name                          | Parts of plant | Source            | Chemical structure | Reference          |
|-----|-------------------------------|----------------|-------------------|--------------------|--------------------|
| 29  | dihydrosanguinarine           | Roots          | Ethanol extract   |                    | Wu et al. (2007)   |
| 30  | dihydrochelerythrine          | Roots          | Ethanol extract   |                    | Wu et al. (2007)   |
| 31  | chelerythrine                 | Whole plant    | Ethanol extract   |                    | Cheng et al. (2008a)|
| 32  | 6-acetonyl-5,6-dihydrosanguinarine | Roots          | Ethanol extract   |                    | Wu et al. (2007)   |
| 33  | 8-acetonyldihydrochelery-thrine | Whole plant    | Methanol extract  |                    | Huang et al. (2012)|
| 34  | protopine                     | Whole plant    | Ethanol extract   |                    | He et al. (2014)   |
| 35  | allocryptopine                | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
| 36  | adlumidine                    | Roots          | Ethanol extract   |                    | Wu et al. (2007)   |
| 37  | oxyacanthine                  | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |

(Continued on following page)
| No. | Name                  | Parts of plant | Source       | Chemical structure | Reference     |
|-----|-----------------------|----------------|--------------|--------------------|---------------|
| 38  | (+)-isocorydine       | Whole plant    | Methanol extract | ![Chemical structure](image) | Cheng et al. (2008a) |
| 39  | (+)-magnoflorine      | Roots          | Ethanol extract | ![Chemical structure](image) | Wu et al. (2007) |
| 40  | saxicolaline A        | Roots          | Ethanol extract | ![Chemical structure](image) | Wu et al. (2007) |
| 41  | pallidine             | Whole plant    | Ethanol extract | ![Chemical structure](image) | He et al. (2014) |
| 42  | (−)-salutaridine      | Roots          | Ethanol extract | ![Chemical structure](image) | Wu et al. (2007) |
| 43  | 2,3-dihydro-5-methoxy-6-methyl-1H-indole | Whole plant    | Methanol extract | ![Chemical structure](image) | Li et al. (2008) |
| 44  | 2,3-dihydro-2-hydroxy-5-methoxy-6-methyl-1H-indole | Whole plant    | Methanol extract | ![Chemical structure](image) | Li et al. (2008) |
| 45  | 14-amino-27ane        | Whole plant    | Ethanol extract | ![Chemical structure](image) | Mao, (2006)    |
| 46  | 14-amino-28ane        | Whole plant    | Ethanol extract | ![Chemical structure](image) | Mao, (2006)    |

(Continued on following page)
| No. | Name                  | Parts of plant | Source            | Chemical structure | Reference       |
|-----|-----------------------|----------------|-------------------|--------------------|-----------------|
| 47  | N-Methylnarceimicine | Roots          | Ethanol extract   |                    | Wu et al. (2007) |
| 48  | corypalline           | Whole plant    | Ethanol extract   |                    | Cheng et al. (2008a) |
| 49  | feruloylagmatine      | Whole plant    | Ethanol extract   |                    | Cheng et al. (2008a) |
| 50  | cholesterol           | Whole plant    | Ethanol extract   |                    | Mao, (2006)     |
| 51  | β-sitosterol          | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
| 52  | cycloeucalenol        | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
| 53  | betulinic acid        | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
| 54  | oleanolic acid        | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
| 55  | betuline              | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
| 56  | β-amyrin acetate      | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
| 57  | daucosterol           | Whole plant    | Ethanol extract   |                    | Wang et al. (2007) |
The results showed that the similarity of 10 batches of CSB samples from different habitats was above 90%. The dehydrocavidine content in the quantitative analysis ranged from 7.85 to 12.71 mg/g. Generally, the content of characteristic constituent dehydrocavidine was determined to evaluate the quality of the plant (Deng et al., 2009). However, it is still urgent to establish a complete set of quality standards for this plant.

### PHARMACOKINETICS

Pharmacokinetics reflects the metabolic process of drugs in vivo, which is affected by different administration methods. Traditional Chinese medicine is mostly administered orally. Therefore, we prefer to identify the evidence supporting its oral effectiveness. Existing studies on the pharmacokinetics of CSB have focused on the monomer constituents. It is known that they are metabolized mainly through the liver and intestines.

Li et al. developed an HPLC coupled with tandem mass spectrometry method for simultaneously quantitating dehydrocavidine, coptisine, dehydroapocavidine and tetradehydroscoulerine in plasma and urine (Li et al., 2006). The results showed the different pharmacokinetic parameters of these four alkaloids in the two states of intravenous and oral administration (Table 2). For intravenous administration, the systemic clearance of these four alkaloids was 180, 147, 111 and 93% of hepatic blood flow in rats, respectively. They could be quickly cleared by the liver in vivo. The major alkaloid constituents of CSB are metabolized by hepatic cytochrome P450s (Yu et al., 2018). Subsequent study by Dai also showed that the liver in pathological states affects the pharmacokinetic parameters of the alkaloid constituents of CSB (Dai et al., 2018). In addition, they had high volumes of distribution (>15.6 L/kg). In all, these alkaloids are metabolized by the liver and are widely distributed in the body. For oral administration, the maximum blood concentrations of the four alkaloids were 88.4 ± 29.8, 19.0 ± 6.52, 115 ± 52.2, and 13.8 ± 5.72 ng/mL. The data were consistent with the proportion of each constituent in the total extract. Correspondingly, their oral bioavailabilities were 13.24 ± 10.86%, 7.21 ± 5.06%, 9.88 ± 6.3% and 10.47 ± 5.42%, respectively. Despite the first pass effect caused by liver, they are still absorbed after the oral administration, which suggests the oral use of CSB. However, the specific metabolic pathway of CSB is yet to be clarified. Other monomeric constituents with pharmacological effects also need more metabolic evidences to support their oral availabilities.

Liu et al. determined dehydrocavidine to explore the characteristics and mechanism of CSBTA absorption in the gastrointestinal tracts of rats by using systemic intestinal circulation and unidirectional perfusion (Liu et al., 2009). They found that CSBTA were absorbed in the digestive tract. At middle (0.20 g/L) and high (1.00 g/L) concentrations, the absorption mechanism was passive diffusion independent of the concentration, which was consistent with the study of Shi (Shi et al., 2013). It also showed that an efflux mechanism of transporters during intestinal mucosal transport of dehydrocavidine. A recent study has confirmed that CSB undergoes the intestinal metabolism (Wu et al., 2021). After intragastric administration of CSB in rats, metabolites of dehydrocavidine, palmatine and berberine were found in blood, urine, bile and feces. These three alkaloids underwent methylation, hydroxylation, demethylation, reduction, glucuronidation and sulfation reactions in vivo. In conclusion, the characteristic metabolism of CSB extract via the liver and intestine after oral administration reasonably explains the use of this ethnomedicine in liver-related disease. In future, oral formulation development may be a favorable direction for the application.

### PHARMACOLOGICAL EFFECTS

The pharmacological effects of constituents or extracts from CSB were investigated and displayed in Table 3.

#### Hepatoprotective Effects

The clearing away heat and detoxification of CSB is linked to its hepatoprotective effects. It demonstrated that CSB alleviated lesions of liver tissue and improved hepatic fibrosis through anti-oxidative stress, reducing live collagen deposition, inflammation and cell apoptosis.

---

**Table 2** | The pharmacokinetic parameters of the four components isolated from CSB in rats.

| Parameters                  | dehydrocavidine | coptisine   | dehydroapocavidine | tetradehydroscoulerine |
|-----------------------------|-----------------|-------------|-------------------|-----------------------|
| **Usage 1**                 |                 |             |                   |                       |
| t1/2 (min)                  | 207 ± 27.6      | 288 ± 112   | 214 ± 104         | 253 ± 170             |
| CL (L/min/kg)               | 0.10 ± 0.02     | 0.08 ± 0.03 | 0.06 ± 0.01       | 0.05 ± 0.01           |
| Vd (L/kg)                   | 27.8 ± 2.78     | 30.1 ± 9.38 | 16.9 ± 5.99       | 15.6 ± 6.81           |
| AUC∞ (mg/L min)            | 38.5 ± 8.36     | 14.6 ± 3.49 | 59.4 ± 11.8       | 8.68 ± 1.60           |
| AUC0-∞ (mg/L min)          | 42.1 ± 9.41     | 20.4 ± 6.54 | 68.0 ± 16.0       | 10.1 ± 1.93           |
| **Usage 2**                 |                 |             |                   |                       |
| t1/2 (min)                  | 154 ± 94.51     | 309 ± 157.2 | 146 ± 101.88      | 312 ± 278.71          |
| AUC∞ (mg/L min)            | 4.61 ± 3.21     | 1.47 ± 1.03 | 6.73 ± 2.49       | 1.06 ± 0.549          |
| AUC0-∞ (mg/L min)          | 5.57 ± 4.57     | 1.47 ± 1.03 | 6.72 ± 4.29       | 1.06 ± 0.549          |
| F (%)                       | 13.2 ± 10.9     | 7.21 ± 5.06 | 9.88 ± 6.3        | 10.5 ± 5.42           |
| Cmax (ng/mL)               | 88.4 ± 29.8     | 19.0 ± 6.52 | 115 ± 52.2        | 13.8 ± 5.72           |
| Tmax (min)                  | 15.0 ± 0        | 13.8 ± 2.5  | 13.8 ± 2.5        | 13.8 ± 2.5            |

| Parameters                  | dehydrocavidine | coptisine   | dehydroapocavidine | tetradehydroscoulerine |
|-----------------------------|-----------------|-------------|-------------------|-----------------------|
| **Intravenous injection, 10 mg/kg** |                 |             |                   |                       |
| t1/2 (min)                  | 207 ± 27.6      | 288 ± 112   | 214 ± 104         | 253 ± 170             |
| CL (L/min/kg)               | 0.10 ± 0.02     | 0.08 ± 0.03 | 0.06 ± 0.01       | 0.05 ± 0.01           |
| Vd (L/kg)                   | 27.8 ± 2.78     | 30.1 ± 9.38 | 16.9 ± 5.99       | 15.6 ± 6.81           |
| AUC∞ (mg/L min)            | 38.5 ± 8.36     | 14.6 ± 3.49 | 59.4 ± 11.8       | 8.68 ± 1.60           |
| AUC0-∞ (mg/L min)          | 42.1 ± 9.41     | 20.4 ± 6.54 | 68.0 ± 16.0       | 10.1 ± 1.93           |
| **Oral administration, 10 mg/kg** |                 |             |                   |                       |
| t1/2 (min)                  | 154 ± 94.51     | 309 ± 157.2 | 146 ± 101.88      | 312 ± 278.71          |
| AUC∞ (mg/L min)            | 4.61 ± 3.21     | 1.47 ± 1.03 | 6.73 ± 2.49       | 1.06 ± 0.549          |
| AUC0-∞ (mg/L min)          | 5.57 ± 4.57     | 1.47 ± 1.03 | 6.72 ± 4.29       | 1.06 ± 0.549          |
| F (%)                       | 13.2 ± 10.9     | 7.21 ± 5.06 | 9.88 ± 6.3        | 10.5 ± 5.42           |
| Cmax (ng/mL)               | 88.4 ± 29.8     | 19.0 ± 6.52 | 115 ± 52.2        | 13.8 ± 5.72           |
| Tmax (min)                  | 15.0 ± 0        | 13.8 ± 2.5  | 13.8 ± 2.5        | 13.8 ± 2.5            |
### TABLE 3  | The pharmacological effects of CSB.

| Pharmacological effects | Component | Detail | Cell lines/model | Administration | Effective dosage | Reference(s) |
|-------------------------|-----------|--------|------------------|---------------|-----------------|--------------|
| **Hepatoprotective effects** | CSBTA | Reduce liver ALT, AST, Hyp, MDA, TGF-β1 and MMP-9 levels; restore TP, ALB and SOD levels; improve liver hypertrophy and fatty lesions; reduce serum TC, TG, LDL-C and NEFA levels; regulate AMPK/PI3K/Akt pathway | Wistar rats | i.g. | 75 and 100 mg/kg | Liang et al. (2008) |
| | | | Male C57BL/6 mice | i.g. | 25 and 100 mg/kg | Chen et al. (2021) |
| | Dehydrocavidine | Reduce serum ALT, AST, ALP, TBIL and Hyp levels; restore GPx, CAT and SOD levels; regulate Bcl2, Cyp3a13, IL18 and Rad50 genes | Sprague Dawley rats | i.p. | 0.5 and 1.0 mg/kg | Wang et al., 2008; Wang et al., 2011 |
| | | | Male Sprague Dawley rats | i.p. | 2.5 g/kg | Liang et al., 2016; Tang and Guangxi, 2017 |
| | | | Male Wistar rats | i.g. | 10 mg/kg | Liu et al. (2019b) |
| | CSB extract | Interferes with amino acid, glucose, lipid metabolism and other metabolic pathways | Male Sprague Dawley rats | i.g. | 0.01–0.10 mg/mL | Lu et al. (2017) |
| | | | Male Sprague Dawley rats | i.p. | 8 mg/kg | Wang et al. (2009) |
| | | | Guangxi brown spot ducklings | i.p. | 3.13, 6.25, 12.50 and 25.00 μM | Zeng et al. (2013) |
| | **Dehydrocistantholine** | Inhibit the secretion of HBsAg and HBeAg; reduce HBV DNA levels | HepG2 cells | — | 0.050 and 0.100 g/L | Li et al. (2007) |
| | | | Tca8113 cells | — | 0.050 and 0.100 g/L | Xu and Liao, (2010) |
| | | | Tca8113 cells | — | 0.200 and 0.300 g/L | Zhu and Liao, (2011) |
| | | | A549 cells | — | 0.005–0.01 g/L | Li (2015) |
| | | | A549 cells | — | 0.01 g/L | Li, 2015; Li et al., 2015; Sang, 2017 |
| | | | A549 cells | — | 5–10 μg/mL | Li et al. (2016b) |
| | | | A549 cells | — | 2.5 and 5 mg/L | Du, (2017) |
| | | | A549 cells | — | 300 mg/kg | Sang, (2017) |
| | **Antitumor effects** | CSBTA | Inhibit cellular telomerase activity | Tca8113 cells | — | 0.050 and 0.100 g/L | Li et al. (2007) |
| | | Inhibit NF-κB P50 and P65 subunits expression | Tca8113 cells | — | 0.1 and 0.2 g/L | Xu and Liao, (2010) |
| | | Inhibit Bcl2 expression | Tca8113 cells | — | 0.200 and 0.300 g/L | Zhu and Liao, (2011) |
| | | | A549 cells | — | 0.005–0.01 g/L | Li (2015) |
| | | | A549 cells | — | 0.01 g/L | Li, 2015; Li et al., 2015; Sang, 2017 |
| | | | A549 cells | — | 5–10 μg/mL | Li et al. (2016b) |
| | | | A549 cells | — | 2.5 and 5 mg/L | Du, (2017) |
| | | | A549 cells | — | 300 mg/kg | Sang, (2017) |
| | Dehydrocavidine | Inhibit hTERT expression | Tca8113 cells | — | 0.050 and 0.100 g/L | Li et al. (2007) |
| | | | Tca8113 cells | — | 0.050 and 0.100 g/L | Xu and Liao, (2010) |
| | | | HepG2 cells | — | 0.4, 0.8 and 1.6 mg/mL | Ju et al. (2018) |
| | | | KM mice | Transdermal administration | 0.77 g/kg | Zhuge et al. (2019) |
| | **Anti-inflammatory and analgesic effects** | CSB extract | Suppress oil-induced mice ear swelling; reduce painful torsional response in mice | KM mice | Transdermal administration | 0.77 g/kg | Zhuge et al. (2019) |
| | | | Female Sprague Dawley rats | Rectal drug administration | 4.2, 8.4 and 16.8 mg/kg | Xiao et al. (2019) |
| | | | THP-1 cells | — | 0.0025 and 0.005 g/L | Feng et al. (2020) |
| | | | Rats | p.o. | 30, 60 and 120 mg/kg | Kuai et al. (2020) |
| | | | Female Wistar rats | i.g. | 50 and 100 mg/kg | Ju et al. (2020) |
| | | | — | — | 50 μg/mL | (Continued on following page) |
Eighty Wistar rats were divided into six groups, including a normal group, a model group, a positive control group bifendate (150 mg/kg), and three CSBTA (from the CSB ethanol extract) groups (50, 75, and 100 mg/kg) (Liang et al., 2008). Except for the normal group, the animals in the other groups were injected subcutaneously with CCl₄ (5 mL/kg 50% CCl₄ for the normal group, the animals in the other groups were injected twice a week for modeling and it lasted for 12 weeks. Correspondingly, the rats in the normal group were given same volumes of peanut oil. Compared with the model, CSBTA (75 and 100 mg/kg) significantly reduced liver ALT, AST, Hyp, MDA, TGF-β1, and MMP-9 levels, and up-regulated decreased TP, ALB, SOD contents in the hepatic fibrosis rats. It was noted that the study only assessed the intervention effect of CSB involved amino acid, bile acid, arginine and proline, and purine metabolism, but other pathways were not considered.

In addition, the anti-hepatic fibrosis mechanism of CSB needs further clarification.

In addition, the effect of CSB on serum metabolomics of liver fibrosis was further explored (Tang and Guangxi, 2017). Forty SD rats were allocated into four groups: a normal, a model, a positive drug colchicines (0.1 mg/kg) and a CSB aqueous extract (2.5 g/kg). The 50% CCl₄ olive oil solution was used for drug colchicines (0.1 mg/kg) and a CSB aqueous extract rats were allocated into four groups: a normal, a model, a positive control group bifendate (150 mg/kg), and three CSBTA (from the CSB ethanol extract) groups (50, 75, and 100 mg/kg) (Liang et al., 2008). Dehydrocavidine (0.5 and 1 mg/kg) was intraperitoneally injected into the animals. The results showed that dehydrocavidine had no hepatotoxicity to healthy rats through analyzing serum biological, lipid peroxide and antioxidative, and histopathological parameters. Also dehydrocavidine above 0.5 mg/kg significantly decreased serum ALT, AST, ALP, TBIL and Hyp levels. In addition, before and after the modeling, dehydrocavidine markedly inhibited MDA product, GPx and SOD consumptions in the liver fibrosis rats, which was better than the positive drug glycyrrhizin (20 mg/kg). Consequently, the urinary excretion of Hyp and the activity of CAT were determined (Wang et al., 2011). Also, they extracted the liver total RNA for microarray analyses to identify the fibrosis-related genes and then validated the results by real-time RT-PCR. It showed that 73 genes involving cell growth, proliferation, apoptosis, cytokines, transcription, and stress, were differentially expressed in the intoxicated rats compared with the control. Among them, four differential expressed genes (Bcl2, Cyp3a13, IL18, and Rad50) were validated. Finally, it was concluded that dehydrocavidine might act on these gene targets to against liver fibrosis.

Lu et al. obtained nine extracts from CSB by different extraction methods. MTT results indicated that each extract inhibited SD rats with liver fibrosis induced by CCl₄ (Wang et al., 2008). Dehydrocavidine (0.5 and 1 mg/kg) was intraperitoneally injected into the animals. The results showed that dehydrocavidine had no hepatotoxicity to healthy rats through analyzing serum biological, lipid peroxide and antioxidative, and histopathological parameters. Also dehydrocavidine above 0.5 mg/kg significantly decreased serum ALT, AST, ALP, TBIL and Hyp levels. In addition, before and after the modeling, dehydrocavidine markedly inhibited MDA product, GPx and SOD consumptions in the liver fibrosis rats, which was better than the positive drug glycyrrhizin (20 mg/kg). Consequently, the urinary excretion of Hyp and the activity of CAT were determined (Wang et al., 2011). Also, they extracted the liver total RNA for microarray analyses to identify the fibrosis-related genes and then validated the results by real-time RT-PCR. It showed that 73 genes involving cell growth, proliferation, apoptosis, cytokines, transcription, and stress, were differentially expressed in the intoxicated rats compared with the control. Among them, four differential expressed genes (Bcl2, Cyp3a13, IL18, and Rad50) were validated. Finally, it was concluded that dehydrocavidine might act on these gene targets to against liver fibrosis.
subsequently verified in the MTT assay and flow cytometry, respectively. The results showed that these three compounds inhibited proliferation and induced apoptosis in the cancer cells. Inhibition rate of palmatine and berberine at 0.10 mg/mL were higher than SB431542, the positive control drug. In addition, it suggested that the safe concentrations of palmatine and berberine were respectively less than or equal to 0.10 and 0.15 mg/mL.

Metabolomics and network pharmacology studies (Liu et al., 2018) revealed that CSB might achieve anti-hepatic fibrosis effects by intervening ALT, FXR, COX-2, MMP-1, AGT, GGT1, FHT and GPD1 targets in rats. The potential active ingredients might be chelerythrine, sanguinarine, cavidine, dehydrocavidine and ferulamide. After reviewing the literatures, it was noticed that a monomer constituent named dehydrocavidine was potentially active among the total alkaloids.

An acute cholestasis rat model was established by α-naphthyl isothiocyanate-olive oil solution and then confirmed by pathological examination (Liu et al., 2019b). The protein expressions of NTCP, BSEP, MRP2 and MRP4 in liver tissue were detected by Western blot. The results showed that CSB water decoction up-regulated the expressions of BSEP and NTCP in the liver tissue, which suggested that CSB could regulate the intake and transfer of bile acids, improve the enterohepatic circulation of bile acid to treat or prevent early mild intrahepatic cholestasis. Interestingly, this study directly used the obtained solution also called “Tang-ji” after decocting CSB, which was consistent with the usage form of TCM. Although this study seems provide some explanations for the application of this ethnomedicine, it is necessary to discuss the pharmacodynamics difference between decoction and aqueous extract.

Chen et al. evaluated the effect of CSBTA on metabolic associated fatty liver disease (Chen et al., 2021). After 10 weeks feeding of high fat and sugar diet, C57BL/6 mice were randomly divided into various groups. The animals in the treatment groups were respectively given CSBTA (25 and 100 mg/kg) and metformin hydrochloride (200 mg/kg). The results showed that CSBTA significantly ameliorated liver hypertrophy and fatty lesions induced by high fat and sugar diet, including decreased serum TC, TG, LDL-C and NEFA levels. Compared with the model control, CSBTA and metformin significantly lowered fasting blood sugar and improved impaired glucose tolerance in the mice. Furthermore, CSBTA up-regulated p-AMPK, p-Pi3K, and p-Akt protein expressions in the liver tissue, which might activate the AMPK/Pi3K/Akt pathway blocked upon the high glucose environment.

It has been highlighted that CSB has inhibitory or killing effects on hepatitis B (Yin, 2001; Li et al., 2008; Zeng et al., 2013). Some studies (Li, 2010; Zhang et al., 2020) suggested that CSB rapidly produced antibodies in vivo and effectively stabilized hepatocyte membranes and mitochondrial membranes. Zeng et al. had evaluated the ability of dehydrocandidathionine to resist hepatitis B virus in vitro (Zeng et al., 2013). Dehydrocandidathionine effectively inhibited the secretion of HBsAg (IC_{50}: 15.84 μM) and HBeAg (IC_{50}: 17.12 μM), and reduce both intracellular and extracellular HBV DNA levels. Also, it promoted bile excretion and hepatocyte regeneration.

An in vivo experiment (Wang et al., 2009) showed that CSB significantly inhibited duck hepatitis B virus (DHBV). Ten-one day-old Guangxi ducks received intraperitoneal injections of 0.2 ml DHBV-DNA positive virus serum. Seven days after the injections, positive infected ducks were selected by PCR and continuously fed until days 13. The animals were divided into six groups including a blank group, a model group, a positive drug group (acyclovir, 0.1 mg/kg), and three CSB groups (2, 4, 8 mg/kg). Compared with the model group, the high-dose CSB group (8 mg/kg) significantly reduced the serum DHBV-DNA, ALT and AST levels, while it was some contradictory to the results of a clinical trial (Li, 2010). The reason might be the clinical use of CSB at concentrations that did not achieve hepatitis B virus suppression. Therefore, it is necessary to evaluate the potential of CSB in clinic more acutely.

Antitumor Effects

Currently, CSB exerts antitumor effects in tongue squamous cell carcinoma, lung cancer and liver cancer.

CSBTA (≤0.200 g/L) inhibited the proliferation and induced cell apoptosis of human tongue squamous cell carcinoma Tca8113, which might be associated with reduced telomerase activity by inhibiting NF-κB activation and Bcl2 expression inhibition at both mRNA and protein levels (Li et al., 2007; Lei and Liao, 2008; Xu and Liao, 2010; Yin and Liao, 2010; Zhu and Liao, 2011). However, whether Bcl2 functions as an upstream target of NF-κB pathway or a target of the apoptotic pathway is still unclear. Among the monomer constituents, dehydrocavidine has been confirmed to inhibit telomerase activity by inhibiting the expression of hTERT protein (Lei and Liao, 2008). Dehydroaporcavidine inhibited the activity of P50 and P65 subunits, thereby inhibiting the activation of NF-κB (Xu and Liao, 2010). And their inhibitory effects were better than CSBTA at the same concentration. Some issues were also present in this study, including the absence of the toxicology of CSB in the cancer cells and the positive control drug.

A series of studies showed that CSBTA inhibited the proliferation, migration, and induced apoptosis of non-small cell lung cancer A549 cells in vitro (Li, 2015; Li et al., 2015; Du, 2017; Sang, 2017; Li et al., 2018b). Flow cytometry showed that CSBTA arrested the cell cycle at phase G1 (Li, 2015). CSBTA ranging 0.005–0.1 g/L inhibited the cell proliferation. In addition, CSBTA displayed a similar inhibitory effect to cisplatin at 0.002 g/L at 48 h (Li et al., 2015). Flow cytometry also showed that CSBTA induced A549 cell apoptosis (Li, 2015; Li et al., 2015). RT-PCR results suggested that CSBTA at 0.01 g/L and cisplatin at 0.002 g/L down-regulated the mRNA level of Survivin, and up-regulated the Caspase-3 mRNA level. Although CSBTA inhibits proliferation, induces apoptosis and arrests the cell cycle, its specific mechanism needs further investigations.

Additionally, CSBTA might inhibit cancer cell migration by the following three pathways. First, CSBTA (0.005–0.01 g/L) increased the mRNA and protein expressions of E-cadherin, decreased the expression of snail, which might inhibit the EMT process (Li, 2015). Second, CSBTA (5–10 μg/mL) directly reduced both mRNA and protein levels of Cdc42, indirectly reduced its downstream factors MMP-2 and MMP-9 protein.
TABLE 4 | The application of CSB.

| Component(s) | Traditional uses | Usage | Reference |
|--------------|------------------|-------|-----------|
| CSB 5 g, Radix gentianae 5 g, borneol 0.01 g | Curing acute conjunctivitis and corneal pannus | Grind into powder, steam and apply to the eyes | Jiangsu New Medical College, (1988) |
| CSB 5 g | Curing hemorrhoidal bleeding and haematochezia | Steam with wine and take orally (100 g) | Jiangsu New Medical College, (1988) |
| CSB 10 g | Curing acute abdominal pain | Take orally | Jiangsu New Medical College, (1986) |
| CSB 3–15 g | Curing hepatitis | Take orally | Chinese Materia Medica Editorial Committee, (1999) |

expressions in the cells, thereby inhibiting the migration and invasion of the A549 cells (Li et al., 2018b). Third, CSBTA reduced F-actin formation in the A549 cells, possibly enhanced Cofilin-1 activity by reducing Cofilin-1 phosphorylation (Du, 2017). After that, it was confirmed the proliferation inhibition in a nude mouse subcutaneous tumor model (Sang, 2017). After subcutaneous injections of A549 cell suspension, BALB/c nude mice were randomly divided into groups. The animals in the treatment groups were treated CSBTA (100 and 300 mg/kg) or cisplatin (2 mg/kg). Twenty-one days after the modeling, tumor volume and mass was determined. The results showed that both CSBTA and cisplatin inhibited the growth of the transplanted tumors. A bone metastasis model was also constructed to evaluate the antitumor effects of CSBTA by injecting the A549 cells into the left ventricle. Compared with the vehicle control group, CSBTA (300 mg/kg) and cisplatin slowed weight loss rate, reduced thoracic metastases, and reduced the serum BALP levels in the mice. These findings provided some in vivo evidences for CSBTA in the treatment of lung cancer. However, the positive control drug cisplatin is not reasonable and bisphosphonate may be a better choice.

In an early experiment in vitro, dehydrocavidine had no significantly inhibitory effect on human liver cancer cell lines HepG2 and QCY-7703 (Huang, 2015). However, a recent study found that CSB water extract inhibited the proliferation and migration of the HepG2 cells, and up-regulated the intracellular NF-κB P65 subunit (Ju et al., 2018). Thus, it is encouraged to confirm the active ingredients in the aqueous extract for the treatment of hepatic cancer.

Anti-inflammatory and Analgesic Effects
The anti-inflammatory effects support its relieving pain. Intraperitoneal administration of CSBTA (50 mg/kg) reduced paw edema in rats with arthritis induced by egg white injection, while it had no significant effect in rats with formaldehyde arthritis at the same dose (Huang et al., 1981). The CSB injection significantly inhibited xylene-induced ear swellings in mice at the early stage of inflammation (Li, 2009). CSB rectal suppository had the similar effect on treating croton oil-induced mouse ear swelling (Zhuge et al., 2019). Meanwhile, CSB at 0.4375 mg/kg inhibited the formation of cotton ball granuloma in mice at late inflammation. Also, CSB rectal suppository showed good analgesic and anti-inflammatory effects in vivo. Xiao et al. found that the CSB suppository (0.77 g/kg) significantly reduced the serum TNF-α and IL-6 levels in rats with pelvic inflammatory disease, and the effect was approximately equivalent to levofloxacin (Xiao et al., 2019). On the basis of the inhibition of inflammatory factor production, a subsequent study suggested that CSBTA might improve the inflammatory environment via effectively suppressing M1 polarization of THP-1-derived macrophages (Feng et al., 2020).

For peripheral neuropathy, CSBTA also showed good anti-inflammatory and analgesic properties both in vivo and in vitro. Kuai et al. evaluated cisplatin-induced peripheral neuropathy in rats. The results showed that CSBTA (30, 60 and 120 mg/kg) by oral administration significantly reduce pain symptoms together with decreased levels of pro-inflammatory cytokine such as TNF-α, IL-1β and PGE2 (Kuai et al., 2020). Importantly, it improved intraepidermal nerve fiber loss and inhibited inflammation-induced p38 phosphorylation to block TRPV1 activation. Xue et al. evaluated paclitaxel-induced peripheral neuropathy in rats and DRG neuron cells of rats (Xue et al., 2021). In vivo, CSBTA (30 and 120 mg/kg) by oral administration reduced TNF-α, IL-1β, PGE2, CGRP and SP levels. CSBTA at 120 mg/kg effectively reduce PKCε, p-p38, MAPK and TRPV1 protein expressions and mRNA levels. The similar effects in vitro required 50 μg/mL of CSBTA. These two studies showed that CSBTA achieves anti-inflammatory and analgesic effects by inhibiting p38 phosphorylation and blocking TRPV1 activation. PKCε is one of the upstream targets of this pathway. However, positive control drugs were missing in these experiments.

In addition, Ju et al. constructed a cancer bone pain model by intraperitoneal injection of 0.5 mL Walker 256 cell suspension into Wistar rats. In vivo, CSBTA significantly alleviated bone pain in rats without obvious adverse effects at doses of 50 and 100 mg/kg. In vitro CSBTA at 50 μg/mL inhibited osteoclastogenesis by inhibiting RANKL-induced NF-xB and c-Fos/NFATc1 pathways (Ju et al., 2020). Overall, CSB achieves its anti-inflammatory and analgesic effects mainly by affecting the production of pro-inflammatory cytokines and regulating related inflammatory pathways.

Antibacterial Effects
CSBTA showed inhibitory effect (MIC: 16.8–130 mg/mL) against common Gram-positive and Gram-negative bacteria in vitro (Qiu et al., 2020). Except for Candida albicans and Pseudomonas aeruginosa (MBC>300 mg/mL), it had a certain bactericidal effect on Staphylococcus aureus, Streptococcus pyogenes, Streptococcus faecalis, Escherichia coli, Helicobacter flexneri, Klebsiella pneumoniae, Salmonella typhi, Salmonella enteritidis and Proteus. Sun et al. determined the antibacterial effect of CSB...
aqueous extract combined with penicillin, cefradine, fosfomycin and levofloxacin respectively on S.aureus (Sun et al., 2020). The results showed that CSB had a synergistic effect when combined with cefradine, penicillin, and levofloxacin (FIC≤0.5). However, unreasonable combination of medicine may enhance toxicity and increase adverse drug reactions. The toxicity of the CSB extract alone or combined with antibiotics need clarification to support its safety in clinical application.

In vivo, Liu et al. investigated the effect of CSBTA on antibiotic-induced gut microbiota dysbiosis (Liu et al., 2019a). After rats received gavage administration of imipenem/cilastatin sodium (50 mg/kg), ten genera were found to be disturbed. But CSBTA at the same dose by oral administration restored four genera of them, especially g_Blautia. The metabolomic results indicate that CSBTA regulates the imbalanced microbiota in the gut mainly through the metabolism of branched-chain amino acid, bile acid, arginine and proline, and purine. Although there are few studies on the antimicrobial properties of CSB, its potential is still worth exploring in this field.

Antioxidant Effects
CSB exhibited antioxidant activity in some in vivo and in vitro experiments. He et al. extracted the whole CSB plant using 70% ethanol and isolated and identified 16 compounds after silica gel column chromatography analysis and spectroscopic analysis (He et al., 2014). In DPPH radical scavenging experiment, CSBTA showed strong antioxidant activity, especially chelanthifoline (IC50: 0.25 mg/mL) and isocorydine (IC50: 1.00 mg/mL). Subsequently, in a MC3T3-E1 cell injury model induced by H2O2 (500 μmol/L) (Shi et al., 2020), MTT result showed that dehydrocavidine ranging 0.001–10 μmol/L had no significant effect on the cell survival. Compared with the model, dehydrocavidine above 0.1 μmol/L or N-acetylcysteine (1 mmol/L) remarkably inhibited the oxidative stress injury, including reduced apoptosis, increased Bcl-2 expression, decreased Bax expression and ROS activity.

The antioxidative effect of CSB has also been confirmed in liver disease models. In addition, dehydrocavidine improved learning and memory impairment induced by d-gala in rats through reducing oxidative damage (Fu et al., 2018). The degree of learning and memory impairment in rats was reduced after 8 weeks of gavage administration of dehydrocavidine at 50 mg/kg. Meanwhile dehydrocavidine decreased SOD, GPx, CAT activity and increased MDA activity in the brain. Interestingly, dehydrocavidine at the same dose did not affect the normal rats, which suggested a low toxicity of this constituent in the brain. However, the positive control drug is absent in this study.

APPLICATIONS
Generally, CSB is called “Yan-huang-lian” in Chinese. Also, it is called “Yan-hu” (Guizhou), “Tu-huang-lian” (Guangxi), “Yan-lian” (Sichuan and Yunnan) (Chinese Materia Medica Editorial Committee, 1999). CSB is bitter and cool in taste. Traditionally, CSB has been use to clear away heat and detoxicate, remove dampness, relieve pain and hemostasis. It has been used to treat acute conjunctivitis (called “huo-yan”), corneal pannus, acute abdominal pain, hemorrhoidal bleeding, haematochezia, swelling, hepatitis, cirrhosis and liver cancer (Jiangsu New Medical College, 1986; Guangxi Zhuang Autonomous Region Department of Health, 1992) (Table 4).

Nowadays, the preparations of CSB mainly include injections, tablets and suppositories. Only the injection preparation is used in clinical practice at present (Luo, 2009). However, its safety is controversial. Given the demonstrated oral effectiveness of CSB, CSBTA capsules are in clinical trials. Capsules may become the primary form for clinical application of this ethnomedicine in the future.

TOXICOLOGY
Currently, there are few complete toxicological studies on CSB. Huang et al. conducted acute and long-term toxicity tests on the CSB extract (Huang et al., 2007). Fifty healthy KM mice were divided into five groups including various doses of CSB at 560, 450, 360, 290, and 230 mg/kg. The animals were administered for three times within 24 h and observed for seven consecutive days. The results showed that the LD50 of the CSB extract was 298.5 mg/kg (95% CI: 257.2–346.5 mg/kg). The long-term toxicity also indicated that the toxicity of the CSB extract was relatively small. However, the details for the experimental process were not mentioned in the study.

Sun evaluated the preclinical safety of the dehydrocavidine injection, including safety pharmacology, acute toxicity, long-term toxicity, allergic, irritation, hemolysis and other toxicities (Sun, 2007). In the safety pharmacology study, intravenous dehydrocavidine ranging from 0.2 to 0.8 mg/kg had no adverse effect on the cardiovascular and respiratory systems of beagle dogs. Intravenous administration of dehydrocavidine had no adverse effect on locomotor activity and pole climbing ability of KM mice. In the acute toxicity test, the intravenous MTD of dehydrocavidine were above 40 and 20 mg/kg in mice and rats, respectively. The intraperitoneal MTD were above 50 and 30 mg/kg in mice and rats. In the long-term toxicity test, after intravenous injection of dehydrocavidine (0.25–2.50 mg/kg) for 180 days in beagle dogs, the animals developed movements such as scratching and salivation after the administration of high-dose dehydrocavidine, while it was recovered after the drug withdrawal. The safe dose of intravenous dehydrocavidine in the beagle dogs was 0.75 mg/kg, and the toxic dose was 2.50 mg/kg. In addition, other toxicity tests showed that dehydrocavidine above the clinical dose did not cause irritation and adverse damage in rabbits and guinea pigs. Therefore, dehydrocavidine showed high safety in the experimental animals. And the toxic reactions caused by overdose in the beagle dogs were mild and reversible. However, this conclusion is not suitable for CSBTA, for dehydrocavidine just one constituent of it.

In some recent in vitro pharmacological studies, researchers have found that high doses of CSBTA (50 μg/mL) was not cytotoxic to a variety of cell lines (Ju et al., 2020; Xue et al.,...
In addition, CSBTA was found to inhibit cytochromes P1A2 (IC50: 38.08 μg/mL), P2D1 (IC50: 20.89 μg/mL), P2C6/11 (IC50 for diclofenac and S-mephenytoin: 56.98 and 31.59 μg/mL), and P2B1 (IC50: 48.49 μg/mL) (Yu et al., 2018). Therefore there is a risk when CSBTA is combined with drugs metabolized by these cytochromes.

Toxicological studies of other constituents in CSBTA also seem to provide some insight into the safety of the drug. The study found that berberine, a constituent of CSBTA, generally was considered safe at clinical doses (Bansod et al., 2021). However, gastrointestinal discomfort, reduced blood pressure, heart damage, shortness of breath and flu-like symptoms might occur at high doses. Besides, berberine exhibited some phototoxicity (Singh et al., 2021). Of concern is that palmatine, another major constituent of CSBTA, exhibited toxicity to a variety of cell lines. Also it produced damage to DNA through oxidative stress (Long et al., 2019). In summary, the safety of CSB needs further assessments.

CONCLUSION

CSB is a commonly ethnomedicine in Southwest China and it has a long history of use in the Chinese folk. In the present study the phytochemistry, pharmacology, applications and toxicology of CSB have been reviewed. Consistent with traditional use, the protective effect of CSB on the liver has been widely recognized. In addition, CSB also has a variety of pharmacological activities such as anti-inflammatory, antioxidiant and anticancer activities.

There are three main types of drug sources in the current studies on CSB: 1) CSBTA; 2) CSB extract; 3) monomer constituent (such as dehydrocavidine). Due to the unstable content of compounds in plants from different regions and the differences in chemical composition between wild and cultivated products, it is difficult to accurately assess the therapeutic concentration of this drug. Thus, establishing quality standards for this medicinal herb is urgent. Furthermore exploring purification methods for CSB monomer constituents is encouraged.

Kinetic studies have shown that the main sites of metabolism of CSBTA are the liver and intestine. Except for few common alkaloids such as dehydrocavidine, pharmacodynamics of other active ingredients is also required. In addition, toxicological studies need to be strengthened as well to support their therapeutic safety.

At present, the pharmacological studies of CSB are still in the stage of identifying active ingredients. So, pharmacological studies should be addressed as follows: 1) the main mechanisms by which CSBTA or other monomeric compounds exert their pharmacological effects; 2) methods to achieve the same efficacy in animal models; 3) evaluating safety and efficacy of the therapeutically potential reagents in clinical trials. In this review, non-hepatic chronic diseases and tumours may be new research directions for this plant. For example, based on the metabolic characteristics of it and pharmacological activity of alkaloid constituents, it suggests the possibility of CSB in intervening intestinal tumors.

In this review, we summarized and analyzed the traditional uses, phytochemistry, pharmacokinetics, pharmacology, toxicity, and applications of Corydalis saxicola Bunting. The issues in the research and development of this plant were proposed as well as the solutions. Further, some new research directions such as anti-tumor, anti-inflammatory related diseases, and analgesia were also provided to utilizing this ethnomedicine more deeply in future.

AUTHOR CONTRIBUTIONS

YG wrote the manuscript; LZ draw most of chemical structures and classified these compounds; JY and JB collected and screened the references; BC analyzed the references; QY corrected the manuscript; JL designed this study.

FUNDING

This work was supported by grants from Guizhou Science and Technology Development Project (2018)2772, Science and Technology Project of Guizhou Science & Technology Bureau (2019)-2-11, Priority majors of Traditional Chinese Medicine and Ethnic Medicine in the “14th Five-Year Plan” of Guizhou Province-Clinical Chinese Materia Medica (QZYYZDKX(JS)-2021-03), Science and Technology Fund Project of Guizhou Provincial Health Commission (2021-462), Science and Technology Development Project of Guizhou Government Guided by China Central Government ((2020)4001), and Scientific Research Project of Guizhou Dendrobium Industry Development Center (2019006).

REFERENCES

Bansod, S., Saifi, M. A., and Godugu, C. (2021). Molecular Updates on Berberine in Liver Diseases: Bench to Bedside. Phytother Res. 35, 5459–5476. doi:10.1002/ptr.7181

Chen, P., Ju, L. J., Chen, J., Diao, H. F., Zhao, K. J., Qiu, Z. X., et al. (2021). Study on Effect and Molecular Mechanism of Corydalis Saxicola Total Alkaloids on Nonalcoholic Fatty Liver Mice. Drug Eval. Res. 44, 468–477. doi:10.19378/jissn.1003-9783.2018.01.021

Cheng, X., Wang, D., Jiang, L., and Yang, D. (2008a). DNA Topoisomerase I Inhibitory Alkaloids from Corydalis Saxicola. Chem. Biodivers 5, 1335–1344. doi:10.1002/cbdv.200890121

Cicero, A. F., and Ertek, S. (2009). Berberine: Metabolic and Cardiovascular Effects in Chronic Disease. Nutr. Dietary Supplements Vol. 1, 1–10. doi:10.2147/NDS.S6084

Dai, G., Sun, B., Wu, L., Gao, X., Song, S., Sun, H., et al. (2018). Comparative Pharmacokinetics of Three Alkaloids in Normal and Acute Hepatitis Rats After
Guo et al. Corydalis saxicola Bunting, an Ethnomedicine

Xie, G., Jin, S., Li, H., Ai, M., Han, F., Dai, Y., et al. (2021). Chemical Constituents of Corydalis Saxicola Bunting: A Review. Tradit. Chinese Drug Res. Clin. Pharmacol. 29, 104–109. doi:10.19378/j.issn.1003-9783.2018.01.021

Tang, C. L., Li, H., Huang, X. M., Shen, Y. D., Huang, Y. H., Song, H., et al. (2019). Quality Assessment of Corydalis Saxicola Bunting Based on HPLC Fingerprint and Multi-Components Quantitative Determination. China J. Traditional Chin. Med. Pharm. 34, 100–104.

Wang, Q. Z., Sun, N. L., and Yuan, Y. (2007). Chemical Constituents of Corydalis Saxicola. Chin. J. Nat. Medicines 5, 31–34.

Tang, C. L., Liu, P., Zheng, H., Song, H., Wang, J., Liang, Y. H., et al. (2018). The Chemical Constituents and Pharmacological Effects of Corydalis saxicola Saxicola Bunting: A Review. Tradit. Chinese Drug Res. Clin. Pharmacol. 29, 104–109. doi:10.19378/j.issn.1003-9783.2018.01.021

Tang, C. L., Yang, H. H., Huang, X. M., Shen, Y. D., Huang, Y. H., Song, H., et al. (2019). Quality Assessment of Corydalis Saxicola Bunting Based on HPLC Fingerprint and Multi-Components Quantitative Determination. China J. Traditional Chin. Med. Pharm. 34, 100–104.

Wang, Q. Z., Li, H. L., Lu, G. C., Yuan, B. J., et al. (2008). Protective Effects of Dehydrocavidine on Carbon Tetrachloride-Induced Acute Hepatotoxicity in Rats. J. Ethnopharmacol 117, 300–308. doi:10.1016/j.jpethoph.2008.02.010

Wang, J., Zhang, S. J., Wu, S. H., and Jiang, W. Z. (2009). Inhibitory Effect of Extract from Corydalis Saxicola Bunting on HBV In Vivo. China Pharmaceutica 18, 7–9.

Wang, T., Zhao, L. J., Li, P., Jiang, H., Lu, G. C., Zhang, W. D., et al. (2011). Hepatoprotective Effects and Mechanisms of Dehydrocavidine in Rats with Carbon Tetrachloride-Induced Hepatic Fibrosis. J. Ethnopharmacol 138, 76–84. doi:10.1016/j.jpethoph.2011.08.039

Wu, Y. R., Ma, Y. B., Zhao, Y. X., Yao, S. Y., Zhou, J., Zhou, Y., et al. (2007). Two New Quaternary Alkaloids and Anti-hepatitis B Virus Active Constituents from Corydalis Saxicola. Planta Med. 73, 787–791. doi:10.1055/s-2007-981549

Wu, Y., Lu, T. L., Ji, D., Zhou, Y., and Mao, C. Q. (2015). Isolation and Structural Identification of Alkaloids from Corydalis Saxicola. J. Nanjing Univ. Traditional Chin. Med. 31, 81–83. doi:10.14148/j.issn.1672-0482.2015.0081

Wu, F., Liu, X., Liang, Y. H., Zheng, H., Su, Z. H., and Song, H. (2021). MDF-based Metabolites of Aqueous Extract of Corydalis Saxicola Bunting in Rats’ Plasma, Urine, Bile and Stool. Lishizhen Med. Materia Med. Res. 32, 28–35.

Xia, J. Z. (2002). Comparison of TLC Between Corydalis Saxicola Bunting and Coptidis Rhizoma. Res. Pract. Chin. Medicines 36. doi:10.2753/csh0099-46330181

Xiao, P., Lin, C. X., Pan, B. J., Zhuge, M. L., Huang, Y., and Zeng, D. Y. (2019). Pharmacodynamics of Yanhuanglian Suppository for Rats with Chronic Pelvic Inflammatory Diseases. Cent. South Pharm. 17, 2052–2058.

Xie, G., Jin, S., Li, H., Ai, M., Han, F., Dai, Y., et al. (2021). Chemical Constituents and Antioxidative, Anti-inflammatory and Anti-proliferative Activities of Wild and Cultivated Corydalis Saxicola. Ind. Crops Prod. 169, 113647. doi:10.1016/j.indcrop.2021.113647

Xu, K., Yuan, X. L., Li, C., and Li, A. X. (2020). Recent Discovery of Heterocyclic Alkaloids from Marine-Derived Aspergillus Species. Mar. Drugs 18, 54. doi:10.3390/md18010054

Xu, R., and Liao, J. X. (2010). Effects of Yanhuanglian Total Alkaloids and Dehydroapocavidine on NF-Kappa B Activity of Oral Carcinoma Cell Lines. J. Oral Maxillofac. Surg. 20, 241–244.

Xue, C., Liu, S. X., Hu, J., Huang, J., Liu, H. M., Qiu, Z. X., et al. (2021). Corydalis Saxicola Bunting Total Alkaloids Attenuate Paclitaxel-Induced Peripheral Neuropathy through PKCε/p38 MAPK/TRPV1 Signaling Pathway. Chin. Med. 16, 58. doi:10.1186/s13020-021-00468-5

Yin, H. (2001). Effect of Yanhuanglian and Danshen Injection on Liver Fibrosis of Chronic Hepatitis B. J. Prat. Med. 17, 782–783.

Yin, J. K., and Liao, J. X. (2010). Effects of Corydalis saxicola Bunting Total Alkaloids on Tca8113 Cell Proliferation and Apoptosis. J. Oral Maxillofac. Surg. 20, 245–248.

Yu, J., Liu, Q., Lu, X., Li, X., Li, N., Liu, B., et al. (2018). Inhibitory and Inductive Effects of Corydalis Saxicola Bunting Total Alkaloids (CSBTA) on Cytochrome P450s in Rats. Phytother Res. 32, 1818–1827. doi:10.1002/ptr.6117

Zeng, F. L., Xiang, Y. F., Liang, Z. R., Wang, X., Huang, D. E., Zhu, S. N., et al. (2013). Anti-hepatitis B Virus Effects of Dehydrocavidine from Corydalis Saxicola. Am. J. Chin. Med. 41, 119–130. doi:10.1142/s0192415x13500092

Zhang, C., Yao, X. D., and Lei, F. H. (2020). Research Progress on Alkaloids in Corydalis Saxicola Bunting. Technology Dev. Chem. Industry 49, 9–13+18. Zhou, Y. Y., Chen, Y. X., Zhu, B., and Xu, X. D. (1989). Study on the Application of HPLC-Diode Array Detection in Proteobeerine Quaternary Alkaloids. Chin. Traditional Herbal Drugs 20, 5–8+46.

Zhu, Y., and Liao, J. X. (2011). Effects of Yanhuanglian Total Alkaloids on Bcl-2 Activity of Oral Squamous Carcinoma Cell Lines. J. Oral Maxillofac. Surg. 21, 96–98.

Zhu, W. M., Li, W. Z., Xiao, P., and Huang, X. Y. (2019). Experimental Study on Anti-inflammatory and Analgesic Effects of Corydalis Saxicola Rectal Suppository. Chin. J. Ethnobotany 28, 11–13.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Guo, Zhao, Chang, Yu, Bao, Yao and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
### GLOSSARY

| Abbreviation | Definition |
|--------------|------------|
| AGT          | angiotensinogen |
| Akt          | protein kinase B |
| ALB          | albumin |
| ALP          | alkaline phosphatase |
| ALT          | alanine aminotransferase |
| AMPK         | adenosine 5’-monophosphate-activated protein kinase |
| AST          | aspartate aminotransferase |
| Bax          | Bcl2-associated x |
| Bcl2         | B-cell lymphoma-2 |
| BSEP         | bile salt export pump |
| CAT          | catalase |
| CCl4         | carbon tetrachloride |
| Cdc42        | cell division cycle 42 |
| COX-2        | cyclooxygenase-2 |
| CSB          | Coradalis Saxicola Bunting |
| CSBTA        | Coradalis Saxicola Bunting total alkaloids |
| CYP          | cytochrome P450 |
| DAD          | diode array detection |
| DHBV         | duck hepatitis B virus |
| DRG          | dorsal root ganglion |
| EMT          | epithelial-mesenchymal transition |
| FHT          | fragile histidine triad |
| FIC          | fractional inhibitory concentration |
| FXR          | farnesoid X receptor |
| GGT1         | gamma-glutamyltransferase 1 |
| GPD1         | glycerol-3-phosphate dehydrogenase 1 |
| GPx          | glutathione peroxidase |
| HHCOSY       | 1H-1H correlation spectroscopy |
| HPLC         | high-performance liquid chromatography |
| hTERT        | human telomerase reverse transcriptase |
| Hyp          | hydroxyproline |
| IL-6/18/1β   | interleukin-6/18/1β |
| KEGG         | kyoto encyclopedia of genes and genomes |
| LDL-C        | low density lipoprotein-cholesterol |
| MBC          | minimum bactericidal concentration |
| MDA          | malondialdehyde |
| MIC          | minimum inhibitory concentration |
| MMP-1/2/9    | matrix metallopeptidase-1/2/9 |
| MRP2/4       | multidrug resistance-associated protein 2/4 |
| MTD          | maximum tolerated dose |
| MTT          | 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
| NEFA         | nonesterified fatty acid |
| NFATC1       | nuclear factor-activated T cell 1 |
| NF-κB        | nuclear factor kappa-B |
| NMR          | nuclear magnetic resonance |
| NTCP         | sodium taurocholate cotransporting polypeptide |
| PGE2         | prostaglandin E2 |
| PI3K         | phosphatidylinositol three kinase |
| PKCe         | protein kinase ε |
| RANKL        | Receptor activator of nuclear factor-κ B ligand |
| RT-PCR       | reverse transcription-polymerase chain reaction |
| SOD          | superoxide dismutase |
| SP           | substance P |
| TBIL         | total bilirubin |
| TC           | total cholesterol |
| TCM          | traditional Chinese medicine |
| TG           | triglyceride |
| TGF-β1       | transforming growth factor-β1 |
| THP-1        | human myeloid leukemia mononuclear cells |
| TNF-α        | tumor necrosis factor-α |
| TP           | total protein |
| TRPV1        | transient receptor potential vaniloid 1 |